WHO Register of non-State actors

Disclaimer:

Information regarding a non-State actor, contained in the section “Non-State Actors Profiles” in the Register, has been provided by that non-State actor itself, and the accuracy and completeness of such information is the sole responsibility of that non-State actor, not WHO. In turn, information in the sections “WHO’s Engagement” and “Non-State Actors in Official Relations” has been provided by WHO, subject to certain conditions. All access and use of any section of the Register is governed by the Terms and Conditions of Use.

Overview

Official name

International Council for Commonality in Blood Banking Automation, Inc.

Acronym (if applicable)

ICCBBA

Short self description

ICCBBA is the international standards organization responsible for the management and development of the ISBT 128 Standard for blood and transplant. The ISBT 128 standard has been designed to ensure the highest levels of accuracy, safety, and efficiency for the benefit of donors and patients worldwide. ISBT 128 provides international consistency to support the transfer, traceability and transfusion/transplantation of blood, cells, tissues and organs.

ICCBBA's vision: Global adoption of ISBT 128 for all medical products of human origin (MPHO).

ICCBBA's mission: Enhancing patient safety by promoting and managing the ISBT 128 international information standard for use with medical products of human origin.

ICCBBA's priorities:
-To manage international information standards for transfusion medicine, transplantation, and other applications of medical products of human origin in support of traceability, biovigilance, and patient safety.
-To liaise with health authorities, regulators, scientific and professional societies, user communities, and vendors on standardization in terminology and information technology.
-To provide educational programs to promote the value of, and need for, information standards and policies to support traceability and biovigilance.
-To provide technical consultation regarding the implementation and management of ISBT 128.
-To lead in the continued development of common data structures for information technology, data processing, exchange and transfer, and labeling for medical products of human origin.

Website

www.isbt128.org

Web link to health relevant activities

Parent entity (if applicable)

The entity you represent is indicated as a parent of the following entities in the Register:

N / A

Date submitted

11 Nov 2025 01:14:35 PM

General information

Name

Official name

International Council for Commonality in Blood Banking Automation, Inc.

Acronym (if applicable)

ICCBBA

Commonly used name (if applicable)

ICCBBA

Names in other official languages (if applicable) Name Abbreviation

International Council for Commonality in Blood Bank Automation Inc

ICCBBA

Former name

Short self description

Address Contact

Address 1

PO Box 11309

Address 2

Address 3

Town/City

San Bernardino

State/Region

Postal code

92423-1309

Country

United States of America

Email (generic)

support@isbt128.org

Organizational Structure

Parent entity

In the register Registered Entity Entity Name

No data available

Yes

Legal status

Affiliated entities (or subsidiaries)

In the register Registered Entity Entity Name

No data available

Relations

Entity's membership in other entities

In the register Registered Entity Entity Name Type of membership

No data available

Yes

The International Society of Blood Transfusion

Partnership with

Yes

Worldwide Network for Blood and Marrow Transplantation

Member of

Members of the entity

In the register Registered Entity Member Name

No data available

Yes

Activities

Aims (or purposes, objectives) of the entity as they appear in its constitution or by-laws or equivalent document.

ICCBBA was established as a self-funded, international, not-for-profit standards organization to:
(a) be organized and operated exclusively for charitable, scientific and educational purposes
(b) support the development, updating, maintenance and promotion of (i) international standards for labeling, data structures and associated code tables for transfusion and transplantation, (ii) related electronic data interchange protocols, and to provide a central focus for information transfer, code assignments and distribution, and technical expertise regarding transfusion and transplantation automation, and (iii) educational materials, programs and policies designed to educate the transfusion and transplantation community particularly, and the public generally, regarding the foregoing purposes and the efforts of ICCBBA in achieving those purposes.

The activities of the entity are related to the following strategic priorities and outcomes of the current WHO's General Programme of Work:

Strategic objective 1: Respond to climate change, an escalating health threat in the 21st century.

Joint outcome 1.1. More climate-resilient health systems are addressing health risks and impacts.

Joint outcome 1.2. Lower-carbon health systems and societies are contributing to health and well-being.

Strategic objective 2: Address health determinants and the root causes of ill health in key policies across sectors.

Joint outcome 2.1. Health inequities reduced by acting on social, economic, environmental and other determinants of health.

Joint outcome 2.2. Priority risk factors for noncommunicable and communicable diseases, violence and injury, and poor nutrition, reduced through multisectoral approaches.

Joint outcome 2.3. Populations empowered to control their health through health promotion programmes and community involvement in decision-making.

Strategic objective 3: Advance the primary health care approach and essential health system capacities for universal health coverage.

Joint outcome 3.1. The primary health care approach renewed and strengthened to accelerate universal health coverage.

Joint outcome 3.2. Health and care workforce, health financing and access to quality-assured health products substantially improved.

Joint outcome 3.3. Health information systems strengthened and digital transformation implemented.

Strategic objective 4: Improve health service coverage and financial protection to address inequity and gender inequalities.

Joint outcome 4.1. Equity in access to quality services improved for noncommunicable diseases, mental health conditions and communicable diseases, while addressing antimicrobial resistance.

Joint outcome 4.2. Equity in access to sexual, reproductive, maternal, newborn, child, adolescent and older person health and nutrition services and immunization coverage improved.

Joint outcome 4.3. Financial protection improved by reducing financial barriers and out-of-pocket health expenditures, especially for the most vulnerable.

Strategic objective 5: Prevent, mitigate and prepare for risks to health from all hazards.

Joint outcome 5.1. Risks of health emergencies from all hazards reduced and impact mitigated.

Joint outcome 5.2. Preparedness, readiness and resilience for health emergencies enhanced.

Strategic objective 6: Rapidly detect and sustain an effective response to all health emergencies.

Joint outcome 6.1. Detection of and response to acute public health threats is rapid and effective.

Joint outcome 6.2. Access to essential health services during emergencies is sustained and equitable.

Additional information on the entity's activities

ICCBBA offers a grant each year called the Enterprise Grant.
Objectives of the Enterprise Grant:

• To build technical capacity in transfusion and/or transplantation activities in terms of safety and efficiency.
• To assist transfusion/transplantation establishments in achieving reliable traceability of all MPHO that they manage.
• To enable ICCBBA to achieve its mission to enhance patient safety through developing and maintaining international information standards for MPHO

See https://www.isbt128.org/grants-and-awards for further information.

Country presence

Countries where the entity has activities, members and regional offices / representatives:

Regions

Countries

Activities

Members

Offices / representatives

African Region

Region of the Americas

Eastern Mediterranean Region

European Region

South-East Asia Region

Western Pacific Region

Global

Disclosure & declaration

Tobacco/Arms related disclosure statement for non-State actors

Pursuant the WHO Framework of Engagement with Non-State Actors, WHO does not engage with the tobacco industry or non-State actors that work to further the interests of the tobacco industry. WHO also does not engage with the arms industry.

For the purposes of this statement:

tobacco industry means any entity involved in the manufacture, sale or distribution of tobacco and related products, and any affiliate of such entity; and
arms industry means any entity involved in the manufacture, sale or distribution of arms, and any affiliate of such entity.

This disclosure statement needs to be provided by any nongovernmental organization, private sector entity, philanthropic foundation and academic institution prior to engaging with WHO.

In view of the foregoing, please answer the following questions:

Is your entity, or was your entity over the last four years, part of the tobacco or arms industries (as defined above)?

Yes

No

Unable to answer

To the best of your entity’s knowledge, is your entity, or has your entity over the last four years, engaged in activities that are aimed at furthering or supporting the interests of the tobacco industry? This includes, but is not limited to, supply contracts, contract work, services and lobbying.

Yes

No

Unable to answer

To the best of your entity’s knowledge, does your entity currently, or did your entity over the last four years, have any other association or relationship with the tobacco industry (as defined above). This includes in particular investment interests (other than general mutual funds or similar arrangements whereby your entity has no control over the selection of the investments), commercial business interests, the provision or receipt of financial and/or other support.

Yes

No

Unable to answer

If you have answered yes to any of the above or are unable to answer one or more questions, please provide a general statement of explanation.

Please note that the WHO Secretariat reserves the right to request additional information from your entity in this regard.

By providing this statement, your entity commits to promptly inform WHO of any change to the above information and to complete a new statement that describes the changes.

Engagement with other industries affecting human health or affected by WHO norm and standards

Does the entity you represent have any formal association, affiliation or links with the following industry sectors?

If yes, please tick the box of the industry concerned and provide details in the space provided:

Alcohol

Chemical

Food and beverages

Health care

The ISBT 128 Standard is used by healthcare facilities to ensure globally unique identification of MPHO. ICCBBA licenses healthcare facilities to use the ISBT 128 Standard.

Pharmaceutical

The ISBT 128 Standard is used by pharmaceutical companies to ensure the chain of identification of MPHO-based therapies e.g. CAR-T cell therapies. ICCBBA licenses these companies to use the ISBT 128 Standard.

Others

Please specify industry

WHO Secretariat reserves the right to request additional information from the entity you represent relevant to its engagement with WHO.

*Sexual Exploitation, Abuse and Harassment (SEAH) and Misconduct (abusive or fraudulent)

Entities engaging with WHO are expected to ensure that the conduct of their employees and any other persons engaged by them to perform any activities or to provide any services for WHO on behalf of the entities is consistent with the WHO standards of conduct. In particular, WHO has zero tolerance towards any form of sexual misconduct, which includes sexual exploitation, sexual abuse, sexual violence, and sexual harassment, and other types of abusive or fraudulent conduct. In the view of the forgoing, please confirm that your entity shall:

Take all reasonable and appropriate measures to prevent sexual misconduct as defined in WHO’s Policy on Preventing and Addressing Sexual Misconduct, and other types of abusive or fraudulent conduct as defined, respectively, in WHO’s Policy on Preventing and Addressing Abusive Conduct and in WHO’s Policy on Prevention, Detection and Response to Fraud and Corruption by any of its employees and by any other persons engaged by it to perform any activities or to provide any services for WHO on the entity’s behalf;

Promptly report to WHO’s Office of Internal Oversight Services (IOS) at investigation@who.int any actual or suspected misconduct, as defined by WHO in these Policies and of which the entity becomes aware;

Promptly communicate to IOS any measures that may be necessary or appropriate to protect the confidentiality and wellbeing of the alleged victim;

Promptly respond to any actual or suspected misconduct as defined by WHO in these Policies of which the entity becomes aware; and

To cooperate with IOS and keep IOS informed of the status and outcome of any measures of protection, corrections to operations, investigation, and disciplinary action taken against any perpetrator by the entity.

Date submitted